MX2022013947A - Formulacion de resiniferatoxina. - Google Patents

Formulacion de resiniferatoxina.

Info

Publication number
MX2022013947A
MX2022013947A MX2022013947A MX2022013947A MX2022013947A MX 2022013947 A MX2022013947 A MX 2022013947A MX 2022013947 A MX2022013947 A MX 2022013947A MX 2022013947 A MX2022013947 A MX 2022013947A MX 2022013947 A MX2022013947 A MX 2022013947A
Authority
MX
Mexico
Prior art keywords
rtx
resiniferatoxin
disclosed
formulation
formulations
Prior art date
Application number
MX2022013947A
Other languages
English (en)
Inventor
Bryan Jones
Alexis Nahama
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2022013947A publication Critical patent/MX2022013947A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen formulaciones más seguras de resiniferatoxina (RTX) para administración intratecal, intraganglionar, intraarticular y pericardial. Más específicamente, se describen formulaciones de RTX sin alcohol que comprenden un componente solubilizante, un monosacárido o alcohol de azúcar, una solución salina amortiguadora y RTX y que tiene rangos estrechos para el rango de pH y gravedad específica.
MX2022013947A 2017-09-11 2020-03-10 Formulacion de resiniferatoxina. MX2022013947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11

Publications (1)

Publication Number Publication Date
MX2022013947A true MX2022013947A (es) 2022-11-30

Family

ID=63708422

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002692A MX2020002692A (es) 2017-09-11 2018-09-11 Formulacion de resiniferatoxina.
MX2022013947A MX2022013947A (es) 2017-09-11 2020-03-10 Formulacion de resiniferatoxina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002692A MX2020002692A (es) 2017-09-11 2018-09-11 Formulacion de resiniferatoxina.

Country Status (9)

Country Link
US (2) US20190076396A1 (es)
EP (1) EP3681472A1 (es)
JP (2) JP7358337B2 (es)
KR (1) KR20200051771A (es)
CN (1) CN111315360A (es)
AU (1) AU2018327301A1 (es)
CA (1) CA3074951A1 (es)
MX (2) MX2020002692A (es)
WO (1) WO2019049112A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
AU2021256948A1 (en) * 2020-04-15 2022-09-01 Grünenthal GmbH Resiniferatoxin compositions
CA3207530A1 (en) * 2021-02-11 2022-08-18 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20050020690A1 (en) * 2002-12-18 2005-01-27 Algorx Infiltration of capsaicin into surgical sites and open wounds
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
US20080139641A1 (en) * 2004-12-28 2008-06-12 Mestex Ag Use Of Resiniferatoxin (Rtx) For Producing An Agent For Treating Joint Pains And Method For Applying Said Agent
PT1830835E (pt) * 2004-12-28 2012-06-25 Mestex Ag Utilização de um agonista do recetor vanilóide em conjunto com um glicosaminoglicano ou proteoglicano para a produção de um agente para o tratamento da dor articular e método para a aplicação do referido agente
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
AU2019403441A1 (en) * 2018-12-21 2021-06-10 Vivasor, Inc. Perineural administration of resiniferatoxin for treatment of maladaptive pain

Also Published As

Publication number Publication date
US20220370405A1 (en) 2022-11-24
AU2018327301A1 (en) 2020-04-09
JP7358337B2 (ja) 2023-10-10
MX2020002692A (es) 2020-10-14
CA3074951A1 (en) 2019-03-14
EP3681472A1 (en) 2020-07-22
CN111315360A (zh) 2020-06-19
JP2020533336A (ja) 2020-11-19
KR20200051771A (ko) 2020-05-13
JP2022176377A (ja) 2022-11-25
WO2019049112A1 (en) 2019-03-14
US20190076396A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2022013947A (es) Formulacion de resiniferatoxina.
EP4338752A3 (en) Stable liquid pharmaceutical preparation
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
EP4302830A3 (en) Quinazoline derivatives used to treat hiv
EP3638248A4 (en) CONJUGATES OF PHARMACEUTICAL INGREDIENTS
EA201691478A1 (ru) Новый полисахарид и его применения
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
WO2018091729A3 (en) Aqueous pharmaceutical formulations
NZ728401A (en) High purity oritavancin and method of producing same
TW201613557A (en) Stable aqueous recombinant protein formulations
MX2017015812A (es) Formulaciones farmaceuticas inyectables de lefamulina.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
WO2019027221A3 (ko) pH 민감성 성분의 안정화용 조성물
EP3849307A4 (en) TWO-CHAMBER VIALS FOR PRESERVING A CORNEAL TRANSPLANT
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1